Complete Genomics Reports $4.2M in Third-Quarter Revenue | GenomeWeb

This article has been updated to correct the operating expenses for the third quarter of 2009.

As it is preparing for its initial public offering, Complete Genomics this week reported $4.2 million in revenue for the third quarter, along with a net loss of $20.5 million.

The company had no revenue during the third quarter of 2009, and a $9.25 million net loss.

As previously stated, Complete Genomics had $9 million worth of backlog orders as of Sept. 30, for which it expects to bill customers within the next 12 months.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.